Evaxion A/S American Depositary Share (EVAX)
EVAX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/0001171843-26-001346-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EVAX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Denmark |
| IPO year | 2021 |
| SEC CIK | 0001828253 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Denmark |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.5M |
| Net income | -$7.7M |
| Operating income | -$9.2M |
| Net margin | -102.4% |
| Operating margin | -122.7% |
| Revenue growth | +125.1% |
| Cash | $23.2M |
| Total assets | $28.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-05 |
| Cash and burn | $23.2M cash; operating cash flow -$1.7M a quarter. | Report 2025-12-31 |
| Shares outstanding | 8,340,215 (2025-12-31); 1,402,611 a year earlier; 482,788 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2025-12-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EY Godkendt Revisionspartnerselskab, Copenhagen, Denmark | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $7.5M | -$7.7M | -$6.6M | $23.2M | $5.5M | $7.5M | 20-F 2026-03-05 |
| FY 2024 2024-12-31 | $3.3M | -$10.6M | -$12.9M | $6.0M | $8.2M | $3.3M | 20-F 2026-03-05 |
| FY 2023 2023-12-31 | $73K | -$22.1M | -$17.7M | $5.6M | $8.6M | $73K | 20-F 2026-03-05 |
| FY 2022 2022-12-31 | $0 | -$23.2M | -$25.8M | $13.2M | $8.0M | $0 | 20-F 2025-04-01 |
| FY 2021 2021-12-31 | Not filed | -$24.5M | -$21.9M | $32.2M | $1.2M | Needs four quarters | 20-F 2024-03-26 |
| FY 2020 2020-12-31 | Not filed | -$15.0M | -$12.4M | $5.8M | No debt tags | Needs four quarters | 20-F 2023-04-28 |
| FY 2019 2019-12-31 | Not filed | -$11.2M | -$7.0M | $9.6M | No debt tags | Needs four quarters | 20-F 2022-03-31 |
| FY 2018 2018-12-31 | Not filed | -$5.5M | -$2.0M | $7.4M | $8.6M | Needs four quarters | 20-F 2021-04-07 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B3 | 424B3 | 2026-11-13 |
| Latest annual report FORM 20-F | 20-F | 2026-03-05 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 370 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.7% |
| 1 month | -0.7% |
| 3 months | -14.7% |
| Year to date | -42.6% |
| 1 year | -52.0% |
| From 52-week high | -58.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MGX | Metagenomi Therapeutics Inc. | $0.6800 | -1.69% | $25.7M |
| PTHS | Pelthos Therapeutics Inc. | $7.15 | -3.90% | $28.1M |
| SAEN | Genenta Science S.p.A. | $0.6000 | -7.66% | $28.9M |
| CVM | Cel-Sci Corporation | $1.66 | +29.69% | $29.2M |
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| BSEM | BioStem Technologies Inc. | $0.9601 | -8.56% | $18.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier